352 Target modulation within the tumor microenvironment (TME) by daratumumab (anti-CD38) but not edicotinib (CSF-1R inhibitor) in men with high-risk localized prostate cancer by Shalini Singh, James Allison, Padmanee Sharma, Sumit Subudhi, Christopher Logothetis, Sonali Jindal, Curtis Pettaway, John Ward, Paul Corn, Bilal Siddiqui, Brian Chapin, Fei Duan, Rebecca Tidwell

Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer by Padmanee Sharma, Sumit Subudhi, James P Allison, Rahul Aggarwal, Eric J Small, Terence W Friedlander, Brandon Chen, Jaqueline Marquez, Kate Allaire, Alexander Cheung, Sharon Ng, Christopher Nguyen, Matthew Spitzer

Get full text

759 ADPORT-601 (TT-10–101): first-in-human study of adenosine 2A (A2A) and adenosine 2B (A2B) receptor antagonists in participants with selected advanced solid tumors by Lawrence Fong, Sumit Subudhi, Gerald S Falchook, Russell Pachynski, Anthony El-Khoueiry, Ian Walters, Robert Krämer, Sushant Kumar, Kasim Mookhtiar, Justin Fairchild, Mohamad A Salkeni, Jaspreet Grewal, William Tester, Samik Upadhaya, Ana Rosa Saez Ibanez, Desa Rae Stanton-Pastore